IL10 promoter genotype aligns with grandiosity in schizophrenia, not the full interleukin panel
Immune signaling continues to shape the biology of psychosis, but most work has focused on negative symptoms, deficit states, and paranoid features. Grandiosity has been left relatively untouched, despite its close relationship to mania and its value as a symptom that can separate competing inflammatory models. In a Polish schizophrenia cohort, investigators tested whether inherited variation across an interleukin pathway panel tracked with this symptom domain. The broader panel was flat. One promoter locus in IL10 was not.
The study drew on 489 patients with schizophrenia who had both genotyping and item-level OPCRIT data available for grandiosity analysis. Grandiosity was defined by two OPCRIT items: inflated self-esteem and grandiose delusions. In the analysis sample, 133 patients, or 27.2%, showed any grandiosity. The mean age at assessment was 31.6 years, and the mean age at onset was 23.1 years. Grandiosity was uncommon enough to make a strong genetic signal noteworthy, yet common enough to map onto a meaningful psychotic phenotype rather than a rare edge case.
The interleukin panel covered 26 functional variants across eight genes: IL1A, IL1B, IL1RN, IL6, IL6R, IL10, IL10RA, and TGFB1. Investigators first asked whether the panel as a whole could predict grandiosity, then moved stepwise into gene-level and locus-level analyses. It could not. Out-of-fold performance was weak, with a Spearman rho of 0.041 and permutation p value of 0.159. In practical terms, the aggregate inflammatory genotype profile did not separate patients with grandiosity from those without it.
A recessive IL10 promoter effect emerged where the full panel failed
The sharpest signal came from IL10, the principal anti-inflammatory cytokine in this network. Gene-set testing showed an association between IL10 and grandiosity (SKAT p = 0.0028, q = 0.023; selection-adjusted p = 0.025). The signal narrowed to the −819/−592 promoter locus, formed from rs1800871 and rs1800872, which are in near-complete linkage disequilibrium in this cohort. Carriage of two copies produced a Firth odds ratio of 5.28, with a 95% confidence interval from 2.37 to 12.48 and p = 4.5 × 10-5. The pattern was consistent with a recessive effect rather than a simple additive one.
The raw frequency difference was striking. Grandiosity was present in 65% of the 26 two-copy carriers, compared with 24% of non-carriers. A single paragraph can carry the clinical weight here: the association was not diffuse, not broadly inflammatory, and not spread across every interleukin marker in the panel. It converged on one promoter locus and one symptom dimension.
Biologically, that matters because IL-10 sits on the anti-inflammatory side of the cytokine balance. The two dominant models of inflammation in psychosis point in opposite directions for grandiosity. If inflammation mainly activates behavior, grandiosity should rise. If inflammation blunts reward signaling and suppresses dopaminergic drive, grandiosity should fall. This locus-level association supports neither model in pure form; instead, it suggests that inherited variation in an anti-inflammatory regulator may help set the threshold at which activation-like symptoms appear. The promoter location also points toward transcriptional control, a plausible route for shifting cytokine tone over time rather than producing an acute state effect alone.
The signal stayed with grandiosity and did not spread across other symptom domains
Specificity testing strengthened the finding. The IL10 effect was tied to grandiosity, with a standardized beta of 0.19 and p = 2 × 10-5. It was only modestly reproducible across split halves, with correlation r = 0.36, and a control analysis using mania as a comparator fell away almost completely, with r = 0.03. Five other symptom dimensions were also examined: manic cluster, depressive dimension, negative dimension, other-delusions dimension, and hallucinations dimension. The IL10 promoter association did not generalize across those domains.
That pattern argues against a broad psychosis severity signal. It instead suggests a phenotype-specific relationship, one that is more informative when the symptom is measured at the level of grandiose beliefs rather than with a coarse global score. Grandiosity is especially useful in this context because it is the symptom for which the inflammation-as-activation model and the inflammation-as-reward-blunting model predict opposite directions. A genetic signal that holds only for grandiosity has more discriminating power than one that simply tracks overall illness burden.
The result also survived several robustness checks. It did not depend on sex, age, or age at onset. The association remained after adjustment for neuroleptic response, after use of alternative SKAT kernels, and after inclusion of panel principal components. It also did not appear to be a case-control risk effect: two-copy carriage at the −819/−592 locus did not differ between the 466 cases and 482 controls in the genotype file. In other words, this looks less like a schizophrenia susceptibility marker and more like a symptom-modifying genotype within affected patients.
What the promoter signal can and cannot say about psychosis biology
The study has clear strengths. It focused on a pre-specified biological pathway, used functional variants rather than a genome-wide scattershot approach, and applied multiple safeguards against overfitting, including held-out splits, jackknife analysis, fragility analysis, and anomaly detection. The analysis also avoided outcome imputation and treated the symptom data carefully at the item level. These steps make the IL10 finding harder to dismiss as a statistical artifact.
Still, the conclusion remains cautious by necessity. The analysis was confined to a single Polish cohort, and the relevant genotype pattern was uncommon enough to require replication in an independent sample. The symptom measure was lifetime-based, not a contemporaneous assessment of current grandiosity. Treatment status at assessment and drug-naive status were not recorded, which limits bedside interpretation. The promoter effect also cannot yet be translated into a direct mechanistic claim about cytokine production because the canonical −1082 variant was null in these data, and the functional direction of the −819/−592 haplotype was not asserted from external assumptions.
Even with those limits, the result is clinically interesting because it pushes immune genetics toward symptom-level precision. A recessive IL10 promoter effect, confined to grandiosity and not to the broader schizophrenia phenotype, suggests that inflammatory regulation may shape how psychosis is expressed rather than whether it is present at all. Independent replication will determine whether this locus genuinely marks a grandiosity-prone subgroup or simply reflects a cohort-specific statistical pocket.